Could an allergy pill ease Parkinson's? new trial launches
NCT ID NCT06785298
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing whether fexofenadine, a common allergy medication, can improve quality of life for people with Parkinson's disease who are already on standard treatment. Researchers will enroll 46 adults aged 50 and older with mild to moderate Parkinson's. The main goal is to see if adding fexofenadine helps reduce symptoms like slowness, stiffness, and tremor.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tanta University
RECRUITINGTanta, 31511, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Planning ahead: could a simple program transform Parkinson's care?
- Sound waves vs. Parkinson's: can ultrasound calm tremors and stiffness?
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can MRI reveal the Brain's response to deep brain stimulation?
- Can we outsmart Gaucher's hidden toll on lungs, bones, and brain?
- Could a brain disease change behavior years before diagnosis?